common sense of nuclear medicine-Hangzhou Jirui Technology Co., Ltd

Common sense of nuclear medicine

1. what is nuclear medicine?

Nuclear medicine, also known as nuclear medicine, mainly uses nuclear medicine to diagnose and treat diseases, including nuclear medicine imaging diagnosis, radionuclide therapy and nuclear medicine in vitro analysis.

2. radiopharmaceuticals

Ji Rui Science and Technology has been deeply engaged in the field of nuclear medicine technology, committed to the development of innovative radioactive diagnosis and treatment drugs with independent intellectual property rights, and has developed a number of new radioactive diagnosis and treatment drugs in the fields of neurological diseases, malignant tumors and tissue inflammation, especially new small molecule nuclear drugs for early diagnosis of mental diseases based on cannabinoid receptor system, and multimodal molecular probes for diagnosis and treatment of solid tumors based on AIE principle have made substantial and innovative breakthroughs. In addition, there are in-depth studies on polypeptides, nucleic acids and other biological macromolecules, such as nanobody nuclear drugs.

Jirui Technology will continue to focus on the development of new innovative drugs and enrich its own radiopharmaceutical pipeline, covering PET, SPECT, nuclide therapy and other AIE multimodal molecular probes in the field of nuclear medicine and molecular imaging.

3. PET drugs

Positron emission tomography (PET) is a type of radioactive drug that is administered clinically and uses specific imaging techniques such as PET (positron emission tomography) to scan and image human organs and tissues. By integrating¹⁸F、¹¹C、¹⁵O、¹³N-class nuclides are labeled on the necessary nutrients (such as glucose, amino acids, water, oxygen, etc.) or drugs in the human body. PET can observe the physiological and biochemical changes of these substances after entering the human body non-invasive, quantitative, and dynamic from the outside, and gain insights into the distribution and activity of metabolites or drugs in the human body at the molecular level.

Figure 1. Positron imaging device (PositronEmissionComputedTomography,PET)

References:

[1](US) Harvey A. Zisman (Harvey A. Ziessman),(US) Janice P. Janis P. O'Malley. NUCLEAR MEDICINE Nuclear Medicine [M], Beijing: Tsinghua University Press. 2018.

[2]Merkel C, Whicher CH, Bomanji J, et al. Realising the potential of radioligand therapy: policy solutions for the barriers to implementation across Europe[J]. Eur J Nucl Med Mol Imaging, 2020, 47(6): 1335-1339.

[3]Pellico J, Gawne P J, T. M. De Rosales R. Radiolabelling of nanomaterials for medical imaging and therapy [J]. Chermical Society Reviews, 2021.

[4]Matthew P.Taggart,a Mark D.Tarn,bc Mohammad M. N. Esfahani,et al.Development of radiodetection systems towards miniaturised quality control of PET and SPECT radiopharmaceuticals[J].Lab Chip, 2016, 16, 1605

[5]Atilio I.Anzellotti*, Aaron R.McFarland, Doug Ferguson and Ken F.Olson.Towards the Full Automation of QC Release Tests for [18F]fluoride-labeled Radio-tracers[J].Current Organic Chemistry, 2013, 17, 2153-2158

free hotline

0571-87701916

13738094495

Mailbox

admin-dept@one-pfm.com

Address

Fengqi Valley Health Industry Park, No. 319 Shenjia Road, Gongshu District, Hangzhou City

SEO

Business License